Mirette Habib, MD
Interventional Cardiology · Newark, NJNPI 1700121365
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Penumbra, Inc. at 49.0% of the total.
Across 250 payments — averaging $59.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$7K
- Abbott$2K
- Philips North America LLC$975
- Abiomed$766
- Novartis$592
- Boston Scientific$397
- plus $3K from 27 others
What the payments were for
- Travel & lodging$6,42043%
- Food & beverage$8,30856%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 33 | $7,266 |
| Abbott | 25 | $1,855 |
| Philips North America LLC | 12 | $975 |
| Abiomed | 9 | $766 |
| Novartis | 39 | $592 |
| Boston Scientific | 4 | $397 |
| Merck | 24 | $371 |
| Amgen | 22 | $331 |
| Cardiovascular Systems Inc. | 4 | $282 |
| AstraZeneca | 6 | $197 |
| Novo Nordisk | 10 | $178 |
| Pfizer | 10 | $161 |
| Stryker | 5 | $158 |
| Impulse Dynamics (USA) Inc. | 2 | $156 |
| Inari Medical, Inc. | 5 | $129 |
| Medtronic | 2 | $110 |
| Shockwave Medical, Inc | 6 | $106 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $104 |
| Astellas Pharma US Inc | 1 | $100 |
| Saranas, Inc. | 1 | $88 |
| E.r. Squibb & Sons, L.L.C. | 6 | $87 |
| Bayer | 4 | $67 |
| Actelion Pharmaceuticals US, Inc. | 4 | $64 |
| Edwards Lifesciences | 2 | $48 |
| Cardiva Medical, Inc. | 2 | $44 |
| Heartflow, Inc. | 2 | $42 |
| Boehringer Ingelheim | 3 | $40 |
| Terumo Medical Corporation | 1 | $37 |
| Atricure, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$6,999
- (9520) IGT Devices Undivided$633
- Perclose ProStyle$615
- Impella$601
- OPTIMIZER$277
- Diamondback Coronary$247
- EMBLEM MRI S-ICD$148
- NAVITOR$143
- Optis Coronary Imaging System$136
- FARXIGA$125
- OPTIS$125
- MitraClip System$112
- JETI$111
- XIENCE SIERRA$107
- RESONATE EL ICD VR$105
- LifeVest$104
How this compares
$14,829 in reported general payments places this provider in the 70th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $88,985 |
| EntrestoSacubitril/Valsartan | 41 | $65,252 |
| FarxigaDapagliflozin Propanediol | 47 | $48,007 |
| BrilintaTicagrelor | 48 | $44,563 |
| VascepaIcosapent Ethyl | 36 | $23,816 |
| JardianceEmpagliflozin | 12 | $11,941 |
| Repatha SureclickEvolocumab | 13 | $9,059 |
| Atorvastatin Calcium | 329 | $4,526 |
| Metoprolol Succinate | 234 | $3,774 |
| Rosuvastatin Calcium | 141 | $3,082 |
| ClopidogrelClopidogrel Bisulfate | 187 | $2,156 |
| Torsemide | 89 | $1,679 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 38 | $1,476 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 30 | $1,459 |
| Hydralazine Hcl | 50 | $1,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $197 | $92,57095 claims |
| PfizerEliquis | $161 | $88,98591 claims |
| NovartisEntresto | $592 | $65,25241 claims |
| Boehringer IngelheimJardiance | $40 | $11,94112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Newark
- Firas QaqaNewark$48K
- Gautam VisveswaranNewark$15K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Matthew SayboltEatontown$175K
- Daniel KissEatontown$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.